Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer
Advances in the development of anti-HER2 monoclonal antibodies (mAbs) represent one of
the most significant milestones in the treatment of HER2+ breast cancer patients. However …
the most significant milestones in the treatment of HER2+ breast cancer patients. However …